Compound class:
Synthetic organic
Comment: ASP2453 is an oral, covalent inhibitor of the mutant KRASG12C protein [1]. It was developed as a potential therapeutic agent for cancers that are KRASG12C positive. ASP2453 is selective for KRASG12C and has no effect on wild-type KRAS protein functions.
![]() Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
References |
1. Nakayama A, Nagashima T, Nishizono Y, Kuramoto K, Mori K, Homboh K, Yuri M, Shimazaki M. (2022)
Characterisation of a novel KRAS G12C inhibitor ASP2453 that shows potent anti-tumour activity in KRAS G12C-mutated preclinical models. Br J Cancer, 126 (5): 744-753. [PMID:34795410] |